Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians
Authors
Keywords
Dapagliflozin, Glycaemic efficacy, Indian population, SGLT2i, Type 2 diabetes
Journal
Diabetes Therapy
Volume 10, Issue 2, Pages 393-428
Publisher
Springer Nature
Online
2019-02-01
DOI
10.1007/s13300-019-0562-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- DECLARE-TIMI 58: Participants’ baseline characteristics
- (2018) Itamar Raz et al. DIABETES OBESITY & METABOLISM
- RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017
- (2018) Sarita Bajaj International Journal of Diabetes in Developing Countries
- Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation
- (2017) Rhona Johnston et al. HEALTH TECHNOLOGY ASSESSMENT
- Sodium-glucose Co-transporter 2 Inhibitors Reduce the Abdominal Visceral Fat Area and May Influence the Renal Function in Patients with Type 2 Diabetes
- (2017) Takahiro Tosaki et al. INTERNAL MEDICINE
- All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database
- (2017) Konstantinos A. Toulis et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes
- (2017) Seon-Ah Cha et al. Lipids in Health and Disease
- Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus
- (2017) Jian Li et al. MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevalence and risk factors of diabetes in a large community-based study in North India: results from a STEPS survey in Punjab, India
- (2017) Jaya Prasad Tripathy et al. Diabetology & Metabolic Syndrome
- Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials
- (2017) Richard E. Gilbert et al. Diabetes Therapy
- Efficacy of Additional Canagliflozin Administration to Type 2 Diabetes Patients Receiving Insulin Therapy: Examination of Diurnal Glycemic Patterns Using Continuous Glucose Monitoring (CGM)
- (2017) Mihoko Matsumura et al. Diabetes Therapy
- Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials
- (2017) Richard E. Gilbert et al. Diabetes Therapy
- Efficacy of Additional Canagliflozin Administration to Type 2 Diabetes Patients Receiving Insulin Therapy: Examination of Diurnal Glycemic Patterns Using Continuous Glucose Monitoring (CGM)
- (2017) Mihoko Matsumura et al. Diabetes Therapy
- Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis
- (2017) Gyeongsil Lee et al. PLoS One
- Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis
- (2016) Christian Sonesson et al. Cardiovascular Diabetology
- Clinical Update: Cardiovascular Disease in Diabetes Mellitus
- (2016) Cecilia C. Low Wang et al. CIRCULATION
- Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm
- (2016) John P.H. Wilding et al. DIABETES CARE
- Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial
- (2016) Eirik Søfteland et al. DIABETES CARE
- SGLT2 Inhibitors and the Diabetic Kidney
- (2016) Paola Fioretto et al. DIABETES CARE
- Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers
- (2016) H. J. L. Heerspink et al. DIABETES OBESITY & METABOLISM
- Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials
- (2016) A. Salsali et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
- (2016) F. Zaccardi et al. DIABETES OBESITY & METABOLISM
- Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
- (2016) Nelson B. Watts et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The effect of dapagliflozin on renal function in patients with type 2 diabetes
- (2016) Donald Elliott Kohan et al. JOURNAL OF NEPHROLOGY
- Efficacy and safety of canagliflozin in patients with type 2 diabetes
- (2016) Wei Xiong et al. MEDICINE
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C
- (2016) Neil Skolnik et al. POSTGRADUATE MEDICINE
- Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
- (2016) R. Devi et al. POSTGRADUATE MEDICINE
- SGLT2 INHIBITORS COMPARED WITH SITAGLIPTIN AS ADD-ON THERAPY TO METFORMIN IN TYPE 2 DIABETES: A SYSTEMATIC REVIEW AND META-ANALYSIS
- (2016) C.A. Sevald et al. VALUE IN HEALTH
- SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
- (2016) Deepson S Shyangdan et al. BMJ Open
- Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial
- (2016) Lancet Diabetes & Endocrinology
- Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
- (2016) Jason H Y Wu et al. Lancet Diabetes & Endocrinology
- Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes
- (2016) Bhavana Sosale et al. Diabetes Therapy
- Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes
- (2016) Bhavana Sosale et al. Diabetes Therapy
- Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective
- (2015) M. Charokopou et al. BMC HEALTH SERVICES RESEARCH
- The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes
- (2015) Pamela M. Katz et al. Canadian Journal of Diabetes
- SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
- (2015) Silvio E Inzucchi et al. Diabetes & Vascular Disease Research
- Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin
- (2015) Ralph A. DeFronzo et al. DIABETES CARE
- Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Giulia Ferrannini et al. DIABETES CARE
- Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus
- (2015) M. J. Davies et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trial
- (2015) S. Ross et al. DIABETES OBESITY & METABOLISM
- Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition
- (2015) S. P. Rajeev et al. DIABETES OBESITY & METABOLISM
- Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data
- (2015) S. Del Prato et al. DIABETES OBESITY & METABOLISM
- Empagliflozin as add-on to metformin in people with Type 2 diabetes
- (2015) L. Merker et al. DIABETIC MEDICINE
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY – CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN – 2015
- (2015) Yehuda Handelsman et al. Endocrine Practice
- Dapagliflozin Lowers Plasma Glucose Concentration and Improves β-Cell Function
- (2015) Aurora Merovci et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diabetes in India
- (2015) Viral N. Shah et al. Current Opinion in Endocrinology Diabetes and Obesity
- Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis
- (2015) Lana Pinto et al. Diabetology & Metabolic Syndrome
- Lifestyle Weight-Loss Intervention Outcomes in Overweight and Obese Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
- (2015) Marion J. Franz et al. Journal of the Academy of Nutrition and Dietetics
- Diabetes Care in India
- (2015) Shashank R. Joshi Annals of Global Health
- Combination therapy of sodium–glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences
- (2015) Awadhesh Kumar Singh et al. Expert Review of Clinical Pharmacology
- Possible adverse effects of SGLT2 inhibitors on bone
- (2015) Simeon I Taylor et al. Lancet Diabetes & Endocrinology
- Comparative Efficacy and Safety of Antidiabetic Drug Regimens Added to Metformin Monotherapy in Patients with Type 2 Diabetes: A Network Meta-Analysis
- (2015) Elizabeth S. Mearns et al. PLoS One
- SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria
- (2014) Yukihiro Chino et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Dapagliflozin as Monotherapy in Drug-Naive Asian Patients With Type 2 Diabetes Mellitus: A Randomized, Blinded, Prospective Phase III Study
- (2014) Linong Ji et al. CLINICAL THERAPEUTICS
- Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin
- (2014) Julio Rosenstock et al. DIABETES CARE
- Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study
- (2014) Lawrence A. Leiter et al. DIABETES CARE
- Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
- (2014) Hans-Ulrich Häring et al. DIABETES CARE
- Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial
- (2014) P.-M. Schumm-Draeger et al. DIABETES OBESITY & METABOLISM
- Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea
- (2014) L. Ji et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis
- (2014) A. Liakos et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise
- (2014) K. Kaku et al. DIABETES OBESITY & METABOLISM
- Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes
- (2014) David Polidori et al. DIABETOLOGIA
- Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis
- (2014) Xu-Ping Yang et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study
- (2014) Nobuya Inagaki et al. EXPERT OPINION ON PHARMACOTHERAPY
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- Prevalence of Dyslipidemia in Urban and Rural India: The ICMR–INDIAB Study
- (2014) Shashank R. Joshi et al. PLoS One
- Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
- (2014) Michael Nauck Drug Design Development and Therapy
- Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial
- (2014) Lancet Diabetes & Endocrinology
- Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
- (2014) Anthony H Barnett et al. Lancet Diabetes & Endocrinology
- Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology
- (2014) Sanjay Kalra Diabetes Therapy
- Dapagliflozin in patients with type 2 diabetes mellitus
- (2014) Theodosios D. Filippatos et al. Therapeutic Advances in Endocrinology and Metabolism
- Renal effects of dapagliflozin in patients with type 2 diabetes
- (2014) Merlin C. Thomas Therapeutic Advances in Endocrinology and Metabolism
- Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline From the American College of Physicians
- (2013) Amir Qaseem et al. ANNALS OF INTERNAL MEDICINE
- Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States
- (2013) Ronald C.W. Ma et al. Annals of the New York Academy of Sciences
- Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
- (2013) Clifford J Bailey et al. BMC Medicine
- Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2
- (2013) Sreeneeranj Kasichayanula et al. CLINICAL PHARMACOKINETICS
- Diabetes in South Asians: Is the Phenotype Different?
- (2013) R. Unnikrishnan et al. DIABETES
- Ethnic Differences in the Relationship Between Insulin Sensitivity and Insulin Response: A systematic review and meta-analysis
- (2013) K. Kodama et al. DIABETES CARE
- Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis
- (2013) S. Goring et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials
- (2013) M. Monami et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
- (2013) J. Bolinder et al. DIABETES OBESITY & METABOLISM
- Changes in Insulin Sensitivity and Insulin Secretion with the Sodium Glucose Cotransporter 2 Inhibitor Dapagliflozin
- (2013) Sunder Mudaliar et al. Diabetes Technology & Therapeutics
- Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
- (2013) Mei Zhang et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
- (2013) F. J. Lavalle-González et al. DIABETOLOGIA
- Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
- (2013) William T Cefalu et al. LANCET
- Bayesian Network Meta-Analysis to Assess the Relative Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled on Metformin and Sulphonylurea (MET+SU)
- (2013) M. Pacou et al. VALUE IN HEALTH
- Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials
- (2013) Asres Berhan et al. BMC Endocrine Disorders
- Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
- (2013) Michael Roden et al. Lancet Diabetes & Endocrinology
- Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study
- (2012) Pedro de Pablos-Velasco et al. CLINICAL ENDOCRINOLOGY
- Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin
- (2012) Ö. Ljunggren et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
- (2012) K. Stenlöf et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial
- (2012) R. R. Henry et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Dietary Weight Loss and Exercise Effects on Insulin Resistance in Postmenopausal Women
- (2011) Caitlin Mason et al. AMERICAN JOURNAL OF PREVENTIVE MEDICINE
- Management of diabetes and associated cardiovascular risk factors in seven countries: a comparison of data from national health examination surveys
- (2011) Emmanuela Gakidou et al. BULLETIN OF THE WORLD HEALTH ORGANIZATION
- Can body fat distribution, adiponectin levels and inflammation explain differences in insulin resistance between ethnic Chinese, Malays and Asian Indians?
- (2011) H Gao et al. INTERNATIONAL JOURNAL OF OBESITY
- Association of BMD and FRAX Score With Risk of Fracture in Older Adults With Type 2 Diabetes
- (2011) Ann V. Schwartz JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Higher leptin levels in Asian Indians than Creoles and Europids: a potential explanation for increased metabolic risk
- (2010) M Lilja et al. INTERNATIONAL JOURNAL OF OBESITY
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
- (2010) Clifford J Bailey et al. LANCET
- Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications
- (2009) J. E. Gerich DIABETIC MEDICINE
- Improved insulin sensitivity after weight loss and exercise training is mediated by a reduction in plasma fatty acid mobilization, not enhanced oxidative capacity
- (2009) Simon Schenk et al. JOURNAL OF PHYSIOLOGY-LONDON
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation